Galectin Therapeutics Files 8-K

Ticker: GALT · Form: 8-K · Filed: May 12, 2025 · CIK: 1133416

Galectin Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyGalectin Therapeutics INC (GALT)
Form Type8-K
Filed DateMay 12, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: filing, corporate-event

Related Tickers: GALT

TL;DR

GALECTIN THERAPEUTICS (GALT) filed an 8-K on 5/12/25 covering disclosures and financials.

AI Summary

Galectin Therapeutics Inc. filed an 8-K on May 12, 2025, reporting on various events including Regulation FD Disclosures, Other Events, and Financial Statements and Exhibits. The company, formerly known as Pro Pharmaceuticals Inc., is incorporated in Nevada and headquartered in Norcross, Georgia.

Why It Matters

This filing provides updates on company events and financial information, which are crucial for investors to assess the company's current status and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically reports on corporate events and does not inherently signal significant new risks.

Key Players & Entities

FAQ

What is the primary purpose of this Form 8-K filing for Galectin Therapeutics Inc.?

The Form 8-K filing reports on various events including Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on May 12, 2025.

What was Galectin Therapeutics Inc. formerly known as?

Galectin Therapeutics Inc. was formerly known as PRO PHARMACEUTICALS INC.

In which state is Galectin Therapeutics Inc. incorporated?

Galectin Therapeutics Inc. is incorporated in Nevada.

What is the principal executive office address for Galectin Therapeutics Inc.?

The principal executive office is located at 4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240, NORCROSS, GA 30071.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 12, 2025 regarding GALECTIN THERAPEUTICS INC (GALT).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing